Clinical Trials Logo

CAS clinical trials

View clinical trials related to CAS.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04825145 Completed - Preeclampsia Clinical Trials

Preeclampsia and Contact Activation

Start date: January 20, 2020
Phase:
Study type: Observational

Preeclampsia (PE) affects approximately 5% of all pregnancies with 2,500 cases registered annually in Denmark. PE is characterized by incomplete modelling of the spiral arteries of the uterus, hypertension, inflammation, hypercoagulability and proteinuria. Neonatal complications and increased cardiovascular risk are common features of the syndrome. PE shares pathophysiologic features with recognized protein misfolding disorders and misfolded proteins are present in urine from women with PE. Misfolded proteins are potent activators of the contact system (CAS) which is involved in inflammation, coagulation and fibrinolysis. Plasminogen activator inhibitor 2 (PAI-2) regulates important fibrinolytic processes in the placenta. The oxidative milieu characterizing PE may trigger misfolding of PAI-2 which then loose inhibitory capacity, but gain CAS-activating capacity. Thus, misfolding of PAI-2 may affect the fibrinolytic system in the placenta and compromise the modelling of the spiral arteries. Moreover, misfolded PAI-2 may contribute to the hypercoagulability and the inflammatory conditions characterizing women with PE. The aim of the present study is i) to characterize CAS in women with PE, ii) to study the CAS-activating capacity of misfolded PAI-2 and iii) to develop and apply immunochemical methods for determination of native and misfolded PAI-2 in plasma.

NCT ID: NCT02022410 Completed - CAS Clinical Trials

CAS and Length of Hospital Stay After TKA

Start date: September 2013
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of the study is to prospectively evaluate patients who underwent total knee arthroplasty (TKA) using the Cumulated Ambulation Score (CAS)